Imfinzi continues to show benefits when added to chemo in first-line ES-SCLC

1 June 2020
astrazeneca_cambridge_large

Updated analysis of the Phase III CASPIAN trial showed Imfinzi (durvalumab) alongside a choice of chemotherapies demonstrated a sustained, clinically-meaningful overall survival (OS) benefit as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC).

Data on the AstraZeneca (LSE: AZN) drug in combination with etoposide plus either carboplatin or cisplatin was presented at the 2020 American Society of Clinical Oncology (ASCO20) Virtual Scientific Program.

This data showed that 11% of patients on Imfinzi plus chemotherapy had not progressed and remained on treatment at two years, versus 2.9% on chemotherapy alone.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology